Skip to main content

Advertisement

Table 2 Clinicopathological and immunohistochemical characteristics of primary breast carcinomas

From: Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis

Variable Categorization IHC Realtime PCR
   n1 % n1 %
Clinicopathological factor:     
Age at diagnosis     
Median, range (years) 57.5 (25–82) 57.5 (28–85)
  ≤ 50 years 54 29.2 10 27.8
  > 50 years 128 69.2 26 72.2
  unknown 3 1.6 0 0
Tumor stage2      
  pT1 46 24.9 15 41.7
  pT2 92 49.7 16 44.4
  pT3 13 7.0 0 0
  pT4 30 16.2 4 11.1
  pTx3 4 2.2 1 2.8
Lymph node status2     
  pN0 71 38.4 19 52.8
  pN1–3 104 56.2 15 41.7
  pNx3 10 5.4 2 5.6
Grading      
  G1/G2 100 54.1 19 52.8
  G3 80 43.2 15 41.7
  Gx3 5 2.7 2 5.6
Histological type      
  ductal 145 78.4 34 94.4
  lobular 13 7.0 1 2.8
  other 19 10.3 1 2.8
  unknown 8 4.3 0 0
Immunohistochemistry (IHC):     
Estrogen receptor status     
  negative (IRS4 0–2) 49 26.5 11 30.6
  positive (IRS 3–12) 97 52.4 21 58.3
  unknown 39 21.1 4 11.1
Progesterone receptor status     
  negative (IRS4 0–2) 107 57.8 12 33.3
  positive (IRS 3–12) 49 26.5 20 55.6
  unknown 29 15.7 4 11.1
HER2 expression status      
  negative (0–1+) 120 64.9 6 16.7
  positive (2+-3+) 38 20.5 5 13.9
  unknown 27 14.6 25 69.4
  1. Characteristics of primary breast carcinomas used for ITIH2 immunohistochemistry (n = 185) and real-time PCR (n = 36) analysis.
  2. 1Only female patients with primary invasive breast cancer were included. 2According to UICC: TNM Classification of Malignant Tumours (2002) [65]. 3x = status unknown. 4IRS = Immunoreactivity score according to Remmele and Stegner (1987) [47].